08:48 AM EDT, 06/02/2025 (MT Newswires) -- Eli Lilly ( LLY ) said Monday its phase 1 trial for its Folate Receptor Alpha-targeting antibody-drug conjugate showed a 55% response rate at the recommended phase 2 dose in platinum-resistant ovarian cancer.

The study enrolled 95 patients, 15% of whom had already been treated using mirvetuximab soravtansine, and the investigational drug demonstrated anti-tumor activity across all four dose levels and FRa expression subgroups, the company said.

Among 58 evaluable patients, the objective response rate was 45% and the disease control rate was 74%, the company reported.

No maximum tolerated dose has been identified, and adverse events were mostly limited to nausea, anemia, fatigue, vomiting, diarrhea, and neutropenia, Lilly said.

The company plans to move the program into phase 3 trials based on the drug's safety and efficacy profile, it said.